In our latest AACR21 Preview — you can check out the whole series here — we turn to some intriguing new product developments coming along the pike.

For many scientists, the lure of the American Association for Cancer Research (AACR) annual meeting isn’t about the glossy phase 1 or 2 clinical readouts, but rather about the early science.

We can think about questions such as are there any new competitors coming along in a particular niche, are there novel targets of interest which can be drugged, what’s rising in the cell therapy space, are there other cells which are seeing interest, and so on.

We cover all of these and more in this review…

To learn more about the hot topics at AACR21 and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by